5-AminoLevulinic Acid Aided Resection Margins in Sarcoma

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2028

Conditions
Soft Tissue Sarcoma (STS)
Interventions
DRUG

5-ALA

5-ALA), also known by its brand name Gleolan, is an intermediate in the heme synthesis pathway that has been studied in tumor resections, especially in intracranial tumor resections. One advantage of intraoperative visualization with 5-ALA is the ability to directly visualize fluorescent tumor in the surgical field using a headset-mounted devices with fluorescence in the visual wavelength in real-time.

Trial Locations (1)

80045

University of Colorado Hospital, Aurora

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

NX Development Corp

INDUSTRY

lead

University of Colorado, Denver

OTHER

NCT07038278 - 5-AminoLevulinic Acid Aided Resection Margins in Sarcoma | Biotech Hunter | Biotech Hunter